CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleLevered free cash flow is $55.92M, above the global median of $18.73M
- FinancialsAltman Z-Score 5.02: safe zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
2.97%Above 5Y avg (2.47%)
Annual Rate
CNY 0.30Paid semi-annual
Payout Ratio
40.7%Sustainable
Payback Period
33.4 yr
Last Ex-Dividend
Sep 18, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
5.12BCNY764.15M · vs all stocks (USD)
Trailing P/E
15.97xvs Medical Devices peers
Revenue (TTM)
1.09BCNY163.42M · vs all stocks (USD)
Profit Margin
27.06%vs Medical Devices peers
Beta
-0.0390xvs all stocks
52-Week Change
25.50%vs all stocks
Forward Annual Dividend Yield
2.97%vs all stocks
Market Capitalization
5.12BCNY764.15M · vs all stocks (USD)
Enterprise Value
3.54BCNY528.38M · vs all stocks (USD)
Trailing P/E
15.97xvs Medical Devices peers
Price to Sales (TTM)
4.37xvs Medical Devices peers
Price to Book (MRQ)
1.63xvs Medical Devices peers
Enterprise to Revenue
3.23xvs Medical Devices peers
Enterprise to EBITDA
10.50xvs Medical Devices peers
Gross Margin
67.92%vs Medical Devices peers
Profit Margin
27.06%vs Medical Devices peers
Operating Margin
19.28%vs Medical Devices peers
Return on Assets (TTM)
4.15%vs Medical Devices peers
Return on Equity (TTM)
10.02%vs Medical Devices peers
Revenue (TTM)
1.09BCNY163.42M · vs all stocks (USD)
Revenue per Share (TTM)
2.20CNYUpdated Sep 22, 2026Quarterly Revenue Growth
7.20%vs Medical Devices peers
Gross Profit (TTM)
737.52MCNY110.13M · vs all stocks (USD)
EBITDA (TTM)
351.58MCNY52.50M · vs all stocks (USD)
Net Income (TTM)
296.14MCNY44.22M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
142.70%vs Medical Devices peers
Operating Cash Flow (TTM)
434.02MCNY64.81M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
374.45MCNY55.92M · vs all stocks (USD)
Forward Annual Dividend Rate
0.3000CNYUpdated Sep 22, 2026Forward Annual Dividend Yield
2.97%vs all stocks
Trailing Annual Dividend Rate
0.3000CNYUpdated Sep 22, 2026Trailing Annual Dividend Yield
2.97%vs all stocks
5-Year Average Dividend Yield
2.47%vs all stocks
Payout Ratio
40.68%vs Medical Devices peers
Minority Interest (Equity)
106.65MCNYFY2025 · Dec 31, 2025Revenue
1.05BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
317.73MCNYFY2025 · Dec 31, 2025Gross Profit
733.99MCNYFY2025 · Dec 31, 2025Operating Income
257.01MCNY38.38M · vs all stocks (USD)
Pre-tax Income
227.69MCNYFY2025 · Dec 31, 2025Income Tax Expense
15.77MCNYFY2025 · Dec 31, 2025Net Income
211.92MCNYFY2025 · Dec 31, 2025EBIT
239.78MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
355.97MCNYFY2025 · Dec 31, 2025Research & Development
157.40MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
79.57MCNYFY2025 · Dec 31, 2025Other Operating Expenses
24.00MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
33.09MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
12.09MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.4400CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.4400CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
501.50MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
501.50MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
211.92MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
8.74MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
231.95MCNYFY2025 · Dec 31, 2025Free Cash Flow
85.76MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
309.16MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
211.92MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-1.27MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
30.39MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-9.09MCNYFY2025 · Dec 31, 2025Capital Expenditures
-146.19MCNYFY2025 · Dec 31, 2025Net Acquisitions
-222.69KCNYFY2025 · Dec 31, 2025Purchase of Investments
-686.02MCNYFY2025 · Dec 31, 2025Sale of Investments
653.54MCNYFY2025 · Dec 31, 2025Other Investing Activity
-35.86MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-214.76MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
779.50MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-880.53MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-103.24MCNYFY2025 · Dec 31, 2025Other Financing Charges
-7.29MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-211.56MCNYFY2025 · Dec 31, 2025Shares Outstanding
507.15MSharesUpdated Sep 22, 2026Float Shares
282.74MSharesUpdated Sep 22, 2026% Held by Insiders
46.11%vs all stocks
% Held by Institutions
1.36%vs all stocks
Total Cash (MRQ)
1.68BCNY250.86M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.32CNYUpdated Sep 22, 2026Total Debt (MRQ)
341.53MCNY51.00M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1121xvs Medical Devices peers
Current Ratio (MRQ)
3.76xvs Medical Devices peers
Book Value per Share (MRQ)
5.80CNYUpdated Sep 22, 2026Total Assets
3.76BCNY560.87M · vs all stocks (USD)
Total Current Assets
2.30BCNYFY2025 · Dec 31, 2025Total Liabilities
896.55MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.45BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
41.38MCNYFY2025 · Dec 31, 2025Total Current Liabilities
855.17MCNYFY2025 · Dec 31, 2025Cash
313.32MCNYFY2025 · Dec 31, 2025Cash Equivalents
563.35KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
313.88MCNYFY2025 · Dec 31, 2025Other Short-term Investments
912.63MCNYFY2025 · Dec 31, 2025Accounts Receivable
359.52MCNYFY2025 · Dec 31, 2025Inventory
183.83MCNYFY2025 · Dec 31, 2025Accounts Payable
190.15MCNYFY2025 · Dec 31, 2025Short-term Debt
480.66MCNYFY2025 · Dec 31, 2025Other Current Liabilities
6.92MCNYFY2025 · Dec 31, 2025Long-term Debt
1.30MCNYFY2025 · Dec 31, 2025Common Stock (Book)
507.15MCNYFY2025 · Dec 31, 2025Retained Earnings
1.73BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.86BCNY426.99M · vs all stocks (USD)
52-Week Low
7.37CNYUpdated Sep 22, 202652-Week High
11.42CNYUpdated Sep 22, 202652-Week Change
25.50%vs all stocks
Beta
-0.0390xvs all stocks
50-Day MA
9.13CNYUpdated Sep 22, 2026200-Day MA
8.91CNYUpdated Sep 22, 2026Avg 10-Day Volume
6.54MSharesUpdated Sep 22, 2026Avg 30-Day Volume
9.51MSharesUpdated Sep 22, 2026Diluted EPS (TTM)
0.5900CNYUpdated Sep 22, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
How does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 5.02: safe zoneNotable
Altman Z-Score: 5.02
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Levered free cash flow is $55.92M, above the global median of $18.73MNotable
Levered free cash flow (USD): 55,916,644.782Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Olema Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Kexing Biopharm Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Obio Technology (Shanghai) Corp., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Design Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Aclaris Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Boji Medical & Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Heilongjiang ZBD Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tong Ren Tang Technologies Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Achieve Life Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tibet Duorui Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Qingdao Haier Biomedical Co., Ltd.
2 interpretationsHigh Retained Earnings With Profitability And EquityMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Great Eastern Shipping Company Ltd.
3 interpretationsHigh Retained Earnings With Profitability And EquityIndustry-Benchmarked ROA and Margin ElevatedMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Hamaton Automotive Technology Co., Ltd.
3 interpretationsHigh Retained Earnings With Profitability And EquityIndustry-Benchmarked ROA and Margin ElevatedMulti-Year Debt Decrease With Cash Near Total Debt And Equity